ALTERITY THERAPEUTICS LTD(ATHE)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

ALTERITY THERAPEUTICS LTD (ATHE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ATHE is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.2m in revenue and is scored on the micro-cap board instead. Top institutional holders of ATHE by reported 13-F value include Twin Lakes Capital Management, MORGAN STANLEY, GREENLEAF, based on the most recent SEC filings. ATHE trades on the Nasdaq exchange and files with the SEC under CIK 1131343. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATHE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALTERITY THERAPEUTICS LTD directly from SEC EDGAR.

ATHE key financials by period

ALTERITY THERAPEUTICS LTD reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 201820-F$201.2K——
FY 201720-F$132.4K——
FY 201620-F$142.7K——

Institutions holding ATHE

Institutional investors reporting a position in ALTERITY THERAPEUTICS LTD on SEC Form 13F.
InstitutionSharesValueReported
Twin Lakes Capital Management139,258$747.8K2026-06-30
MORGAN STANLEY63,065$338.7K2026-06-30
GREENLEAF62,000$332.9K2026-06-30
HB Wealth Management58,460$313.9K2026-06-30
CITADEL ADVISORS37,597$201.9K2026-06-30
HRT FINANCIAL17,292$92.0K2026-06-30
BNP PARIBAS FINANCIAL MARKETS10,239$55.0K2026-06-30
GAMMA Investing2,309$12.4K2026-06-30
RHUMBLINE ADVISERS2,009$10.8K2026-06-30
ACADIAN ASSET MANAGEMENT1,863$10.0K2026-06-30
SEC EDGAR: CIK 1131343 →
ATHE

ALTERITY THERAPEUTICS LTD

ATHE
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.2M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Financial metrics will appear once SEC EDGAR data is ingested for this company.

Top Institutional Holders

as of Q2 2026
$2.12M total
Twin Lakes Capital Management, LLC
$747.8K0.0%
MORGAN STANLEY
$338.7K+8.0%
GREENLEAF TRUST
$332.9K+93.8%
HB Wealth Management, LLC
$313.9K0.0%
CITADEL ADVISORS LLC
$201.9K+87.3%
HRT FINANCIAL LP
$92.0KNew
BNP PARIBAS FINANCIAL MARKETS
$55.0K+50.4%
GAMMA Investing LLC
$12.4K+24.4%
RHUMBLINE ADVISERS
$10.8K+2.0%
ACADIAN ASSET MANAGEMENT LLC
$10.0K0.0%
Loading ratio trend…